


# PRODUCT INFORMATION



## Foretinib

Item No. 16249

**CAS Registry No.:** 849217-64-7  
**Formal Name:** N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide  
**Synonyms:** GSK1363089, XL880  
**MF:** C<sub>34</sub>H<sub>34</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>  
**FW:** 632.7  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 242 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Foretinib is supplied as a crystalline solid. A stock solution may be made by dissolving the foretinib in the solvent of choice. Foretinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of foretinib in ethanol and DMF is approximately 25 mg/ml and approximately 16 mg/ml in DMSO.

Foretinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, foretinib should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Foretinib has a solubility of approximately 0.25 mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Foretinib is a broad-spectrum tyrosine kinase (TK) inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRβ, and Tie-2, at nanomolar concentrations.<sup>1,2</sup> It blocks HGF-induced Met phosphorylation and VEGF-induced ERK phosphorylation, preventing HGF-induced responses in tumor cells and HGF/VEGF-induced responses in endothelial cells.<sup>1,3</sup> Foretinib is functional *in vivo*, reducing tumor burden in an experimental model of lung metastasis.<sup>1</sup>

### References

1. Qian, F., Engst, S., Yamaguchi, K., *et al.* Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. *Cancer Res.* **69**(20), 8009-8016 (2009).
2. Davis, M.I., Hunt, J.P., Herrgard, S., *et al.* Comprehensive analysis of kinase inhibitor selectivity. *Nat. Biotechnol.* **29**(11), 1046-1051 (2011).
3. Mughal, A., Aslam, H.M., Sheikh, A., *et al.* c-Met inhibitors. *Infect. Agent. Cancer* **8**, 13 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM